Medigene to Present at ESMO Congress 2024
23 July 2024 - 10:15AM
Planegg/Martinsried, July 23, 2024.
Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard),
an immuno-oncology platform company focusing on the discovery and
development of T cell immunotherapies for solid tumors, today
announced the presentation of two posters at the ESMO Congress 2024
being held on September 13-17, 2024, in Barcelona, Spain. The
posters will be showcasing recent advancements in the Company’s
library of T cell receptors (TCR) targeting Kirsten rat sarcoma
viral oncogene homologue (KRAS) as well as its UniTope & TraCR
technology, a universal tagging and tracking system for TCR-T
cells.
The full abstracts will be published online on the
ESMO website (https://www.esmo.org/) on Monday, September 9, 2024,
at 00:05 am CEST.
Details of the poster presentations are as
follows:
Abstract and title: “Advancing a multi-dimension
KRAS mutation-specific T cell receptor (TCR) library with a 3S TCR
targeting the G12D mutation to address large global patient
populations.”
Authors: Kirsty Crame, Dominik Alterauge, Anne
Wiebe Mohr, Julia Bittmann, Doris Brechtefeld, Mario Catarinella,
Kathrin Davari, Maja Buerdek, Petra U Prinz, Andrea Coluccio,
Dolores J Schendel and Giulia LonginottiFinal presentation number:
1143PDate/time: Saturday, September 14, 2024, Poster lunch session
from noon to 1:00 pm CEST in Hall 6, poster will be on display from
9:00 am to 5:00 pm CESTCategory: Investigational Immunotherapy
Abstract and title: “UniTope & TraCR -
Universal tagging and tracking system for TCR-T cells integrated
directly in the TCR constant region.”
Authors: Kirsty Crame, Kanuj Mishra, Justyna
Ogonek, Dolores Schendel and Barbara Lösch Final presentation
number: 1144P Date/time: Saturday, September 14, 2024, Poster lunch
session from noon to 1 pm CEST in Hall 6, poster will be on display
from 9:00 am to 5:00 pm CEST Category: Investigational
Immunotherapy
--- end of press release ---
About Medigene AG
Medigene AG (FSE: MDG1) is an immuno-oncology
platform company dedicated to developing differentiated T cell
therapies for treatment of solid tumors. Its End-to-End Platform is
built on multiple proprietary and exclusive technologies that
enable the Company to generate optimal T cell receptors against
both cancer testis antigens and neoantigens, armor and enhance
these T cell receptor engineered (TCR) -T cells to create
best-in-class, differentiated TCR-T therapies, and optimize the
drug product composition for safety, efficacy and durability. The
End-to-End Platform provides product candidates for both its own
therapeutics pipeline and partnering. Medigene’s lead TCR-T program
MDG1015 is on track for IND filing in Q3 2024 and CTA filing in Q4
2024. For more information, please visit https://medigene.com/
This press release contains forward-looking
statements representing the opinion of Medigene as of the date of
this release. The actual results achieved by Medigene may differ
significantly from the forward-looking statements made herein.
Medigene is not bound to update any of these forward-looking
statements. Medigene® is a registered trademark of Medigene AG.
This trademark may be owned or licensed in select locations
only.
Medigene AG
Pamela Keck Phone: +49 89 2000 3333 01 E-mail:
investor@medigene.com
In case you no longer wish to receive any
information about Medigene, please inform us by e-mail
(investor@medigene.com). We will then delete your address from our
distribution list.